111 related articles for article (PubMed ID: 29658363)
1. Therapy of cervical cancer using
Li W; Sun D; Li N; Shen Y; Hu Y; Tan J
J Int Med Res; 2018 Jun; 46(6):2359-2370. PubMed ID: 29658363
[TBL] [Abstract][Full Text] [Related]
2. Antitumor Effect of Nanoparticle
Ming H; Fang L; Gao J; Li C; Ji Y; Shen Y; Hu Y; Li N; Chang J; Li W; Tan J
AJR Am J Roentgenol; 2017 May; 208(5):1116-1126. PubMed ID: 28301223
[TBL] [Abstract][Full Text] [Related]
3. RGD(Arg-Gly-Asp) internalized docetaxel-loaded pH sensitive liposomes: Preparation, characterization and antitumor efficacy in vivo and in vitro.
Zuo T; Guan Y; Chang M; Zhang F; Lu S; Wei T; Shao W; Lin G
Colloids Surf B Biointerfaces; 2016 Nov; 147():90-99. PubMed ID: 27497073
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
[TBL] [Abstract][Full Text] [Related]
5. Encapsulation of eptifibatide in RGD-modified nanoliposomes improves platelet aggregation inhibitory activity.
Bardania H; Shojaosadati SA; Kobarfard F; Dorkoosh F; Zadeh ME; Naraki M; Faizi M
J Thromb Thrombolysis; 2017 Feb; 43(2):184-193. PubMed ID: 27778144
[TBL] [Abstract][Full Text] [Related]
6. Anticancer activity of targeted proapoptotic peptides.
Capello A; Krenning EP; Bernard BF; Breeman WA; Erion JL; de Jong M
J Nucl Med; 2006 Jan; 47(1):122-9. PubMed ID: 16391196
[TBL] [Abstract][Full Text] [Related]
7. Targeting effect of PEGylated liposomes modified with the Arg-Gly-Asp sequence on gastric cancer.
Ding J; Feng M; Wang F; Wang H; Guan W
Oncol Rep; 2015 Oct; 34(4):1825-34. PubMed ID: 26238930
[TBL] [Abstract][Full Text] [Related]
8. RGD-modified pH-sensitive liposomes for docetaxel tumor targeting.
Chang M; Lu S; Zhang F; Zuo T; Guan Y; Wei T; Shao W; Lin G
Colloids Surf B Biointerfaces; 2015 May; 129():175-82. PubMed ID: 25851582
[TBL] [Abstract][Full Text] [Related]
9. RGD conjugated liposome-hollow silica hybrid nanovehicles for targeted and controlled delivery of arsenic trioxide against hepatic carcinoma.
Fei W; Zhang Y; Han S; Tao J; Zheng H; Wei Y; Zhu J; Li F; Wang X
Int J Pharm; 2017 Mar; 519(1-2):250-262. PubMed ID: 28109899
[TBL] [Abstract][Full Text] [Related]
10. RGD-modified liposomes enhance efficiency of aclacinomycin A delivery: evaluation of their effect in lung cancer.
Feng C; Li X; Dong C; Zhang X; Zhang X; Gao Y
Drug Des Devel Ther; 2015; 9():4613-20. PubMed ID: 26316700
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Radioiodine- or Radiobromine-Labeled RGD Peptides between Direct and Indirect Labeling Methods.
Ogawa K; Takeda T; Yokokawa M; Yu J; Makino A; Kiyono Y; Shiba K; Kinuya S; Odani A
Chem Pharm Bull (Tokyo); 2018; 66(6):651-659. PubMed ID: 29863067
[TBL] [Abstract][Full Text] [Related]
12. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer.
Wang F; Chen L; Zhang R; Chen Z; Zhu L
J Control Release; 2014 Dec; 196():222-33. PubMed ID: 25456829
[TBL] [Abstract][Full Text] [Related]
13. Liposomalized oligopeptides in cancer therapy.
Asai T; Oku N
Methods Enzymol; 2005; 391():163-76. PubMed ID: 15721380
[TBL] [Abstract][Full Text] [Related]
14. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
[TBL] [Abstract][Full Text] [Related]
15. [Preparation and evaluation of RGD and TAT co-modified paclitaxel loaded liposome].
Gao B; Mu W
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Aug; 39(8):769-74. PubMed ID: 25202944
[TBL] [Abstract][Full Text] [Related]
16. Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis.
Koning GA; Schiffelers RM; Wauben MH; Kok RJ; Mastrobattista E; Molema G; ten Hagen TL; Storm G
Arthritis Rheum; 2006 Apr; 54(4):1198-208. PubMed ID: 16575845
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of therapeutic effectiveness of (131)I-antiEGFR-BSA-PCL in a mouse model of colorectal cancer.
Li W; Ji YH; Li CX; Liu ZY; Li N; Fang L; Chang J; Tan J
World J Gastroenterol; 2016 Apr; 22(14):3758-68. PubMed ID: 27076760
[TBL] [Abstract][Full Text] [Related]
18. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
19. Increased tumor targeted delivery using a multistage liposome system functionalized with RGD, TAT and cleavable PEG.
Mei L; Fu L; Shi K; Zhang Q; Liu Y; Tang J; Gao H; Zhang Z; He Q
Int J Pharm; 2014 Jul; 468(1-2):26-38. PubMed ID: 24709209
[TBL] [Abstract][Full Text] [Related]
20. [(131)I labeling and bioactivity evaluation of a novel RGD dimer targeted to integrin αvβ3 receptor].
Zhang CL; Wang RF; Zhang L; Guo FQ; Li L; Kang L; Yan P; Yang M
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Apr; 43(2):295-300. PubMed ID: 21503130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
